Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-019B in refractory systemic lupus erythematosus
NCT07444307Phase 1Recruiting
- Sponsor
- Qihan Biotech
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QT-019B in systemic lupus erythematosus (SLE), sponsored by Qihan Biotech. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
QT-019B
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07444307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444307.